ADMIT

admit-therapeutics.com LinkedIn

ADmit Therapeutics has a CE-marked test that predicts whether mild cognitive impairment will progress to Alzheimer's, built on a mitochondrial DNA biomarker.

Sector

Healthtech

Mida de l'empresa

11-50

A Barcelona

1-10

Fundada el

2017

Destacats d'IA Evidència pública, comprovada set. del 2026

Producte A disruptive CE-marked in vitro prognostic solution based on the first mitochondrial DNA epigenetic biomarker for Alzheimer's dementia, employing Next Generation Sequencing and Machine Learning techniques . Names the technique "machine learning", on its own site set. del 2026 ↗

Al campus

Encara no hi ha sessions previstes amb ADMIT.

Vols sentir-los? Digue'ns de què t'agradaria que parlessin i els ho demanarem.

Vull sentir-los